Boston Scientific Announces Results from Promus Premier, Synergy Drug-Eluting Stent
May 22, 2013 at 09:18 AM EDT
Boston Scientific Corporation (NYSE: BSX ) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, and